<DOC>
	<DOC>NCT00838097</DOC>
	<brief_summary>This European study observes paediatric patients with Chronic Kidney Disease using Darbepoetin Alfa to assess the drug's long term safety and profile the patterns of its use within this population.</brief_summary>
	<brief_title>European Union Registry in Paediatric Chronic Kidney Disease Patients Looking at Safety and Usage Patterns of Darbepoetin Alfa</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Anaemia attributed to Chronic Kidney Disease (CKD) Sixteen years of age or under Documented CKD as demonstrated by estimated glomerular filtration rate (eGFR) &lt;60 mL/min/1.73m² (Schwartz equation) for ≥3 months if not on dialysis, or: Receiving dialysis Treatment with darbepoetin alfa Documented informed consent by a parent or authorised individual, if required, and assent by the patient if appropriate Active malignancy or current chemotherapy or radiation therapy Investigator unlikely to be able to obtain adequate followup information, or participant will not be available for followup assessment Currently enrolled in or has not yet completed at least 30 days since ending other investigational device or drug study; subject receiving other investigational agents</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>CKD</keyword>
	<keyword>Paediatric</keyword>
	<keyword>Darbepoetin Alfa</keyword>
</DOC>